There are differences among patients with CLL who are receiving treatments such as Bruton Tyrosine Kinase (BTK) inhibitors and those who are in “watch and wait”, but all are at high-risk of fatal outcomes [8,9]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.